^This innovative method has the potential, new treatment options for
to open up chronic diseases through mitochondrial dysregulation
to be caused.
Houston, March 05, 2025 (Globe Newswire) – Fibrobiologics, Inc. (Nasdaq: FBLG)
(? Fibrobiologics “), a biotechnology company working in the clinical stage
With over 160 granted and registered patents that are on the development
of therapeutic agents and potential remedies for chronic diseases under
Use of fibroblasts and materials derived from fibroblasts
concentrated, has submitted a patent application to the United States
Patent and Trademark Office announced, the procedures for improving the
Mitochondrial performance in cells using fibroblasts.
Mitochondria are vital organelles that are for the cellular
Energy production are responsible for oxidative phosphorylation. One
Mitochondrial dysregulation is on the aging process and on a variety of
Diseases involved, including Autoimmun, neurodegenerative, metabolism and
Muscle diseases. Fibroblasts, primary cells for secretion and
Maintaining connective tissue, bioactive molecules like
Growth factors, cytokines and extracellular vesicles, the cellular
Influence the micro environment.
The modulation of the mitochondrial function by local or systemic
Admission of fibroblasts provides a new method for treatment
mitochondrial dysregulation – an area in the medical
Research increasingly focuses on. This new approach has this
Potential to open up new treatment options for diseases that
caused by mitochondrial dysfunction and for the pathology of many
contribute to chronic diseases.
? The use of fibroblasts to improve the micro environment of the cells
By modulating mitochondrial activity, the potential, treatment
to fundamentally change chronic diseases and have a positive effect on the
I have a life expectancy of man, “said Pete O’Heeron, founder and chief
Executive Officer from Fibrobiologics.
? In the research community is the interest in the use of therapies,
that aim at mitochondria, for the treatment of chronic diseases
increased, “said Hamid Khoja, Chief Scientific Officer from fibrobiologics.?unser
Approach uses the natural ability of fibroblasts, the mitochondrial
Function to modulate and may open new therapeutic
Strategies for the treatment of several chronic diseases. “
You can find more information on the Fibrobiologics website
(https://www.fibrobiologics.com/) or send an email to fibrobiologics
at: [email protected] (mailto: [email protected]).
Important note on future -oriented statements
This communication contains? Future -oriented statements “in the sense of the private
Securities Litigation Reform Act from 1995.
Information about the potential of fibroblasts, the mitochondrial function
to modulate new treatment options for mitochondrial dysfunctions
open up to change the treatment of chronic diseases and new
Therapeutic strategies for the treatment of multiple chronic diseases
to open up. These future -oriented statements are based on the current
Expectations, estimates, forecasts and beliefs in the management of
Fibrobiologics and on a number of assumptions regarding future
Events. These future -oriented statements are not guarantees for
Future services, conditions or results and contain a number
Known and unknown risks, uncertainties, assumptions and other important important ones
Factors from which many outside the control of management of
Fibrobiologics that could lead to the factual
Results essentially of the statements mentioned in the future -oriented statements
Deviating results, including the one under the heading? Risk factors “
and elsewhere in the annual, quarterly and current reports of
Fibrobiologics (ie form 10-k, form 10-Q and form 8-k)
were submitted or presented at the SEC, and all subsequent
public submissions. Copies are on the SEC website
Available, www.sec.gov (http://www.sec.gov/). To these risks, imponderables,
Assumptions and other important factors include: (a) risks in the
Connection with the liquidity of Fibrobiologics and its ability to
to provide sufficient capital resources for the management of its business;
(b) Expectations regarding the introduction, progress and the expected
Results of our F & e-efforts and preclinical studies; (c) The
unpredictable relationship between f&- and preclinical results and the
Results of clinical studies; and (d) the ability of Fibrobiologics, his
To successfully pursue patent applications. Future -oriented statements apply
Only for the date of their publication. Readers are pointed out to themselves
not to rely excessively on future -oriented statements, and fibrobiologics
assumes no obligation and does not intend to do these future -oriented
To update or revise statements, be it due to new
Information, future events or for other reasons unless
This is required by law. Fibrobiologics does not provide any assurance that
the company will meet its expectations.
About fibrobiologics
Fibrobiologics is a biotechnology company based in Houston, which im
clinical stage is active and a pipeline of treatments and potential
Survey for chronic diseases using fibroblast cells
and materials derived from fibroblasts. Fibrobiologics holds
Over 160 US and internationally granted patents/registered patents
In various clinical areas, including interdependencies,
Orthopedics, multiple sclerosis, psoriasis, wound healing, reversal of the
Organ involution and cancer. Fibrobiologics stands for the next generation of
Medical progress in cell therapy. You can find more information
At www.fibrobiologics.com
(https://www.globenewswire.com/tracker?data=t1ovw9yuopf8vun9xrub0wekaoercds065BU
ZF7LGZN-F5EBLAZORU_MQVLKPY62RAT51RKHJXJWTNV2AG-NUTRC5IYUWUQL0CMSUIPIC =).
General inquiries:
[email protected] (mailto: [email protected])
Investor relationships:
Nic Johnson
Russo partners
(212) 845-4242
[email protected] (mailto: [email protected])
Media contact:
Liz Phillips
Russo partners
(347) 956-7697
(mailto: [email protected])
 °